v2.4.0.6

Collaboration Arrangements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2011
Collaboration Arrangements |
Schedule of common stock shares purchased in private placements by the affiliate of GSK |
|  | Through December 31, 2011 |
--- | --- | --- | ---
|  | Common Stock Shares Purchased |  | Aggregate Amounts (in thousands) |
Purchase dates |  |  |  |  |  |  |
February 24, 2011 |  |  | 152,278 |  | $ | 3,609 |
May 3, 2011 |  |  | 261,299 |  | $ | 6,689 |
August 2, 2011 |  |  | 102,466 |  | $ | 2,020 |
November 1, 2011 |  |  | 58,411 |  | $ | 1,298
Schedule of upfront license fees and milestone payments received from GSK under the LABA collaboration and strategic alliance agreements |
|  | Through December 31, 2011 |
--- | --- | --- | ---
(in thousands) |  | Upfront License Fees |  | Milestone Payments |  | Total |
GSK Collaborations |  |  |  |  |  |  |  |  |  |
LABA/RELOVAIR™ collaboration(1) |  | $ | 10,000 |  | $ | 50,000 |  | $ | 60,000 |
Strategic alliance agreement |  |  | 20,000 |  |  | — |  |  | 20,000 |
Strategic alliance—LAMA license(2) |  |  | 5,000 |  |  | 3,000 |  |  | 8,000 |
Strategic alliance—MABA program license |  |  | 6,000 |  |  | 16,000 |  |  | 22,000 |
Total |  | $ | 41,000 |  | $ | 69,000 |  | $ | 110,000 |
(1) The Company does not currently expect to be eligible for any additional milestones under this collaboration. (2) In August 2004, GSK exercised its right to license the Company's LAMA program pursuant to the terms of the strategic alliance. In 2009, GSK returned the program to the Company.
Schedule of revenue recognized from GSK under the LABA collaboration and strategic alliance agreements |
|  | Year Ended December 31, |
--- | --- | --- | ---
(in thousands) |  | 2011 |  | 2010 |  | 2009 |
LABA/RELOVAIR™ collaboration(1) |  | $ | 4,718 |  | $ | 5,081 |  | $ | 5,081 |
Strategic alliance agreement |  |  | 1,858 |  |  | 2,738 |  |  | 2,738 |
Strategic alliance—LAMA license |  |  | — |  |  | — |  |  | 4,240 |
Strategic alliance—MABA program license(2) |  |  | 3,082 |  |  | 2,007 |  |  | 3,014 |
Total revenue |  | $ | 9,658 |  | $ | 9,826 |  | $ | 15,073 |
(1) In the fourth quarter of 2011, the Company revised the estimated performance period for the LABA program based on its progress. The Company does not expect that the revisions will have a material impact on future revenue recognized under this program. (2) In the fourth quarter of 2011 and the first quarter of 2010, the Company revised the estimated performance period for the MABA program based on its progress. The Company does not expect that the revisions will have a material impact on future revenue recognized under this program.
Schedule of revenue recognized under the Astellas collaboration agreement |
|  | December 31, |
--- | --- | --- | ---
(in thousands) |  | 2011 |  | 2010 |  | 2009 |
Amortization of deferred revenue |  | $ | 12,975 |  | $ | 12,975 |  | $ | 11,338 |
Royalties from net sales of VIBATIV® |  |  | 2,422 |  |  | 1,123 |  |  | 766 |
Proceeds from VIBATIV® delivered to Astellas |  |  | 1,171 |  |  | 2,058 |  |  | — |
Cost of VIBATIV® delivered to Astellas |  |  | (1,177 | ) |  | (938 | ) |  | (1,629 | )
Cost of unrealizable VIBATIV® inventory |  |  | (537 | ) |  | (821 | ) |  | (1,175 | )
Total net revenue |  | $ | 14,854 |  | $ | 14,397 |  | $ | 9,300

X
- Definition Tabular disclosure of the common stock shares and the aggregate value purchased in private placements by an affiliate of an entity with which there is a collaboration agreement. + References No definition available. + Details
Name: | thrx_CollaborationArrangementsCommonStockActivityTableTextBlock
Namespace Prefix: | thrx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | thrx_CollaborationArrangementsDisclosureAbstract
Namespace Prefix: | thrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue recognition by the entity related to Astella collaboration agreement. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementRevenueRecognitionAstellaCollaborationTableTextBlock
Namespace Prefix: | thrx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the upfront fees and milestone payments received by the entity pursuant to collaboration and strategic alliance agreements related to long-acting beta-2 agonist (LABA) products during the period. + References No definition available. + Details
Name: | thrx_ScheduleOfCollaborativeArrangementsUpfrontFeesAndMilestonePaymentsReceivedTableTextBlock
Namespace Prefix: | thrx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the revenue recognized through amortization of the deferred upfront fees and milestone payments received by the entity under the collaboration and strategic alliance agreements related to long-acting beta-2 agonist (LABA) products during the period. + References No definition available. + Details
Name: | thrx_ScheduleOfCollaborativeArrangementsUpfrontFeesAndMilestonePaymentsRevenueRecognizedLABATableTextBlock
Namespace Prefix: | thrx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration